ASH 2023 | The evolving role of transplantation in multiple myeloma in the age of novel immunotherapeutics
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, speaks on the changing role of stem cell transplantation (SCT) in treating multiple myeloma (MM), given the rise in novel immunotherapeutics. Dr Giralt references the PERSEUS (NCT03710603) and GRIFFIN (NCT02874742) trials as evidence for the efficacy of SCT alongside high-dose chemotherapy and predicts that the need for SCT in multiple myeloma treatment will persist; however, its role will become increasingly nuanced. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Amgen, Actinuum, Celgene/BMS, Omeros, Johnson & Johnson, Miltenyi, Takeda
Board of Directors/Advisory Committee: Amgen, Actinuum, Celgene/BMS, Kite Pharma, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, Novartis, Spectrum Pharma, Takeda
